Government delays could threaten a £450m investment in a huge new vaccine facility in Liverpool, according to reports. Last ...

AstraZeneca's bold vision for a cutting-edge vaccine facility in Speke is caught in a web of delays, leaving the biotech ...

A barrage of grim UK economic data this month has given chancellor Rachel Reeves “permission” to pursue a more aggressive growth agenda, according to senior government officials, trampling on Labour ...

Tech Climbers returns to the Liverpool City Region next month for a fifth year, celebrating half a decade of profiling the ...

A £650 million investment package by AstraZeneca in the UK has been held ... to invest £450 million at its manufacturing site in Speke, Liverpool, to boost research, development, and ...

AstraZeneca is backing up its considerable ... investment in an expansion of its vaccines manufacturing facility in Speke, near Liverpool, and a new facility at its R&D headquarters in Cambridge ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...